{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-24-000053","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2024-08-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.772601+00:00","generated_at":"2026-05-31T08:38:59.517519+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Supernus announces FDA accepted resubmission of SPN-830 NDA; PDUFA date Feb 1, 2025","bullets":["FDA acknowledged resubmission of NDA for SPN-830 (apomorphine infusion device) for continuous treatment of motor fluctuations in Parkinson's disease.","Resubmission is considered filed; user fee goal date (PDUFA) set for February 1, 2025.","SPN-830 targets OFF episodes in Parkinson's disease; Supernus focuses on CNS therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-24-000053","json":"https://secwatch.observer/filing/0001356576-24-000053.json","markdown":"https://secwatch.observer/filing/0001356576-24-000053.md","text":"https://secwatch.observer/filing/0001356576-24-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657624000053/0001356576-24-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657624000053/supn-20240819.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:38:59.517519+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}